Intelligence Profile
Safety Profile
The current safety profile of glycerol tributyrate (also known as tributyrin) is limited, with few specific studies focused directly on its side effects, contraindications, or drug interactions in humans. Here is what can be gathered from available evidence:
Side Effects: Direct evidence on side effects in humans is not available from the provided studies. Tributyrin itself has been studied in animal models, such as pigeons and shrimp, primarily focusing on its effects on immune function and growth [PMID: 42193838, 42193789]. However, translating these findings to humans should be done cautiously.
Contraindications and Interactions: There is no direct evidence regarding contraindications or drug interactions involving glycerol tributyrate. The absence of data means that clinicians should exercise caution and consider potential interactions based on the compound's metabolism pathways, primarily involving butyrate.
Populations to Avoid Use: Specific populations that should avoid using glycerol tributyrate are not identified in the provided data. The absence of clinical trial results (e.g., NCT06792500), which are not yet recruiting, suggests safety information in targeted populations, such as patients with MELAS or LHON-Plus, is forthcoming but currently unavailable.
Clinical Trial Considerations: The ongoing and future clinical studies (e.g., NCT06792500) may provide more comprehensive safety data once results are available. Until then, healthcare providers should stay informed about new findings.
Due to the limited evidence on glycerol tributyrate's safety in humans, healthcare providers are encouraged to proceed with caution, monitor for potential side effects, and consult updated research findings as they become available.
Disclaimer: This information is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a healthcare provider for medical concerns.